Real-World Evidence and Real-world Data: Beyond Payer Decisionmaking
Although payer decision-making has been a key use of real-world evidence (RWE) and real-world data (RWD) in the healthcare space, there are far more avenues in which these resources can advance medicine. Agencies like the US Food and Drug Administration (FDA) are increasingly using RWE and RWD to make regulatory decisions, while market access teams implement strategies based on the perspectives they inform.
Webinar: Make Market Access Your Brand’s Super Power
Accessibility is a key deciding factor for clinicians when prescribing medicine. At an upcoming webinar on August 23rd, Jon Bambalas [...]
Webinar: Planning for the Pivot to Commercialization – August 25th
Achieving commercial success in cell and gene therapy requires careful planning from the early stages of preclinical development. On August [...]
R-S-S Course: Economic Evalulation of Cancer Drugs – October 3rd
Regulatory Scientific and Health Solutions (R-S-S) is hosting a course entitled, “Economic Evaluation of Cancer Drugs.” The course is aimed towards professionals in health economics and outcomes research (HEOR), market access, and clinical oncology. Attendees will learn about the development, application, and interpretation of economic models for cancer drugs. The course takes place at the Hilton London Watford, Watford, UK on Monday 3rd October 2022. Register by 1st August 2022 for an early bird discount.
Fishawack Health Teams Up with Avalere to Expand Market Access Offerings
The market access and health economics and outcomes research (HEOR) consulting experts at Fishawack Health have added Avalere Health to [...]
Accelerating Market Access to Medical Advances With Lumanity
Lumanity, a company focused on bringing new therapeutics to patients, has launched today. Despite recent medical advances in drug development [...]
